PDCD1LG2 and breast carcinoma: Next, we investigated the impact of HT, RT, and HT in combination with RT on the expression of immune inhibitory ICMs (PD-L1, PD-L2, HVEM) and on one immune stimulatory ICM (OX40-L) on MCF-7 and MDA-MB-231 breast cancer cells.